Abstract:Heat shock protein 90 (HSP90) has emerged as an important target in cancer treatment because many of its clients are crucial in malignant transformation. HSP90 inhibitors such as antibiotic anismycin Geldanamycin and its derivatives 17-AAG promote degradation of client proteins. Several preclinical observations have made HSP90 inhibitors attractive drugs to the treatment of cancer. First, HSP90 inhibitors may provide a broader and effective anticancer therapy. Second, HSP90 in tumor cells was shown to exhibit much higher affinity for its inhibitors. HSP90 inhibitors such as 17-AAG and 17-DMAG are currently used targeting a variety of tumors in clinical trials. The TGFβ signaling pathway represents a major tumor suppressor pathway in normal epithelial cells, and paradoxically, it also acts as a significant promoter of tumor progression, invasion and metastasis in carcinomas. Since tumors are often detected in late stages, inhibition of TGFβ signaling pathway may be beneficiary to cancer patients. Several attempts in the past several years have highlighted the potential of blocking TGFβ responses in tumors by using soluble TGFβ receptors or competitive small molecules targeting the TGFβ receptors in anti-cancer therapy. Notably, the toxicity of TGFβ inhibition is well tolerated in mouse models, suggesting the strong potential of anti-TGFβ therapeutics in cancer. Our recent identification that TGFβ receptors are client proteins of HSP90 provides novel insights into the potential of HSP90 inhibitors in anti-cancer therapies. Objective: (1) To elucidate the molecular mechanisms underlying essential role of HSP90 in controlling TGFβ signaling in normal and cancer cells; (2) To explore the potential of HSP90 inhibitors as anti-metastasis therapeutics in breast cancer. Methods: Using a proteomic approach, we found an association between HSP90 and TGFβ receptors (both TβRI and TβRII). Further TβR-HSP90 interaction, TβR turnover and Smad2 phosphorylation were carried out using immunoprecipitation and western blotting. Dosage and duration of treatment with HSP90 inhibitors GA, 17-AAG, and Ridicicol were initially established by evaluating the blockade of TGFβ-induced Smad2 phosphorylation. Effect of HSP90 inhibitors and HSP90 siRNAs on the expression of TGFβ target gene transcription will be assessed by real-time RT-PCR. Cell proliferation was assayed by 3H-thymidine incorporation, and cell invasiveness was done in BD Matrigel Invasion Chambers in MDA-MB-231 breast carcinoma cells. Results: Using biochemical assays, we confirmed that TGFβ receptors (both TβRI and TβRII) physically associated with HSP90 proteins in a variety of normal and cancer cells. We next found that inhibition of HSP90 functions by several HSP90 inhibitors can promote the rapid turnover of TGFβ receptors in a ubiquitination/proteasome-dependent manner. Consequently, HSP90 inhibitors inhibit TGFβ-mediated phosphorylation of tumor suppressors SMAD2 and SMAD3, and block TGFβ-dependent transcription of genes such as MMP9. At the cellular level, HSP90 inhibitors led to the blockade of TGFβ-induced invasiveness of MDA-MB-231 breast carcinoma cells. Conclusion: We have identified HSP90 inhibitors as potential drugs blocking TGFβ functions. This study should help to understand the mechanisms of TGFβ and HSP90 interplay in progression of human cancers. Our study will also provide invaluable information on the use of HSP90 inhibitors for the treatment of human cancers.

QS288. Potent Blockade of TGF-β Signaling by HSP90 Inhibitors

Critical Regulation of TGFβ Signaling by Hsp90

Inhibitors of the HSP90 Molecular Chaperone: Current Status

Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance

Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects

Inhibition of Heat Shock Protein 90 As a Novel Platform for the Treatment of Cancer.

Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.

Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

An update on the status of HSP90 inhibitors in cancer clinical trials

Natural HSP90 inhibitors as a potential therapeutic intervention in treating cancers: A comprehensive review

Inhibition of Gastric Tumor Growth by a Novel Hsp90 Inhibitor

Inhibition of Heat Shock Protein 90 Suppresses TWIST1 Transcription.

Therapeutic and diagnostic implications of Hsp90 activation